The data of 174 postmenopausal patients with abnormal uterine bleeding admitted were assessed to determine associated risk factors and develop and validate a prediction model to evaluate the risk of endometrial cancer in these patients. The patients were divided into a study group and a control group, among which 62 patients were diagnosed with endometrial cancer. A binary logistic regression analysis model using multifactorial regression analysis was established, and a column line graph of the prediction model was created using the R software. The model’s goodness-of-fit test was performed using the Hosmer-Lemeshow test, and SPSS (version 27, International Business Machines Corporation, Armonk, NY, USA) was used to plot the receiver operating characteristic (ROC) curve to evaluate the model’s predictive value. Binary logistic multifactorial regression analysis revealed that elevated body mass index (BMI), human epididymal protein 4 (HE4), cancer antigen 125 (CA125), combined fibroids and thickened endometrial cancer were risk factors for endometrial cancer in patients with abnormal postmenopausal uterine bleeding, based on which a probability model for predicting the risk of developing endometrial cancer in patients with abnormal postmenopausal uterine bleeding was constructed, and represented as P = 1/[1 + exp (4.227 − 4.594X1 − 2.029X5 − 1.165X6 − 1.817X7 − 2.080X8)]. In addition, the goodness-of-fit test, assessed using Hosmer and Lemeshow, yielded an χ2 value of 14.253 and a p-value of 0.075. Furthermore, the ROC curve analysis demonstrated an area under the curve (AUC) of 0.993 (95% confidence interval (CI), 0.892–0.974; p < 0.05). In conclusion, elevated BMI, HE4 and CA125, along with the presence of combined fibroids and thickened endometrial lining, were identified as significant risk factors for endometrial cancer in postmenopausal patients with abnormal uterine bleeding. The risk prediction model developed in this study provides a scientifically sound approach to assess the risk of endometrial cancer in these patients.
对174例绝经后子宫异常出血患者的资料进行评估，以确定相关危险因素，并建立和验证预测模型，以评估这些患者发生子宫内膜癌的风险。将患者分为研究组和对照组，其中诊断为子宫内膜癌的患者62例。采用多因素回归分析建立二元logistic回归分析模型，并利用R软件绘制预测模型的柱线图。采用Hosmer-Lemeshow检验对模型进行拟合优度检验，并采用SPSS(第27版，International Business Machines Corporation, Armonk, NY, USA)绘制受试者工作特征(ROC)曲线来评价模型的预测值。二元logistic多因素回归分析结果显示，体质指数(BMI)升高、人附睾蛋白4 (HE4)、癌抗原125 (CA125)、合并肌瘤和子宫内膜癌增厚是绝经后异常子宫出血患者发生子宫内膜癌的危险因素，并在此基础上构建了绝经后异常子宫出血患者发生子宫内膜癌的概率模型。用P = 1/[1 + exp(4.227−4.594X1−2.029X5−1.165X6−1.817X7−2.080X8)]表示。此外，采用Hosmer和Lemeshow进行拟合优度检验，其χ2值为14.253,p值为0.075。此外，ROC曲线分析显示曲线下面积(AUC)为0.993(95%置信区间(CI)， 0.892-0.974; p <0.05)。综上所述，BMI、HE4、CA125升高以及合并肌瘤和子宫内膜增厚是绝经后子宫异常出血患者发生子宫内膜癌的重要危险因素。本研究建立的风险预测模型为评估这些患者发生子宫内膜癌的风险提供了一种科学合理的方法。
{"title":"Analysis of risk factors and construction and validation of a predictive model for determining the risk of endometrial cancer in postmenopausal patients with abnormal uterine bleeding","authors":"","doi":"10.22514/ejgo.2023.077","DOIUrl":"https://doi.org/10.22514/ejgo.2023.077","url":null,"abstract":"The data of 174 postmenopausal patients with abnormal uterine bleeding admitted were assessed to determine associated risk factors and develop and validate a prediction model to evaluate the risk of endometrial cancer in these patients. The patients were divided into a study group and a control group, among which 62 patients were diagnosed with endometrial cancer. A binary logistic regression analysis model using multifactorial regression analysis was established, and a column line graph of the prediction model was created using the R software. The model’s goodness-of-fit test was performed using the Hosmer-Lemeshow test, and SPSS (version 27, International Business Machines Corporation, Armonk, NY, USA) was used to plot the receiver operating characteristic (ROC) curve to evaluate the model’s predictive value. Binary logistic multifactorial regression analysis revealed that elevated body mass index (BMI), human epididymal protein 4 (HE4), cancer antigen 125 (CA125), combined fibroids and thickened endometrial cancer were risk factors for endometrial cancer in patients with abnormal postmenopausal uterine bleeding, based on which a probability model for predicting the risk of developing endometrial cancer in patients with abnormal postmenopausal uterine bleeding was constructed, and represented as P = 1/[1 + exp (4.227 − 4.594X1 − 2.029X5 − 1.165X6 − 1.817X7 − 2.080X8)]. In addition, the goodness-of-fit test, assessed using Hosmer and Lemeshow, yielded an χ2 value of 14.253 and a p-value of 0.075. Furthermore, the ROC curve analysis demonstrated an area under the curve (AUC) of 0.993 (95% confidence interval (CI), 0.892–0.974; p < 0.05). In conclusion, elevated BMI, HE4 and CA125, along with the presence of combined fibroids and thickened endometrial lining, were identified as significant risk factors for endometrial cancer in postmenopausal patients with abnormal uterine bleeding. The risk prediction model developed in this study provides a scientifically sound approach to assess the risk of endometrial cancer in these patients.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136366595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Platinum-based chemotherapy is commonly used in the treatment of various cancers, including epithelial ovarian cancer (EOC). However, in EOC, chemotherapy failure is mainly caused by platinum resistance. In this present study, we aimed to identify novel biomarkers for predicting platinum chemosensitivity. Fresh specimens of 16 serous high-grade ovarian cancer (HGSC) cases were collected during cytoreductive surgery. Isobaric tags were used to identify differentially expressed proteins in platinum-resistant samples (n = 8) and platinum-sensitive samples (n = 8). Compared to platinum-sensitive samples, 741 significantly differentially expressed proteins were detected, of which 325 were upregulated and 416 were downregulated. To validate the isobaric tags for relative and absolute quantification (iTRAQ) method, western blotting was performed on two upregulated proteins, angiomotin-like protein 1 (AMOTL1) and Lumican. The results showed that platinum-resistant tumor samples expressed significantly higher levels of AMOTL1 and Lumican than platinum-sensitive tumor samples. Altogether, we identified candidate proteins related to platinum resistance in ovarian cancer. Both AMOTL1 and Lumican seem to be promising biomarkers that could distinguish between platinum-resistant and platinum-sensitive EOC.
{"title":"iTRAQ-based proteomics analysis reveals novel candidates for platinum resistance of epithelial ovarian cancer","authors":"","doi":"10.22514/ejgo.2023.074","DOIUrl":"https://doi.org/10.22514/ejgo.2023.074","url":null,"abstract":"Platinum-based chemotherapy is commonly used in the treatment of various cancers, including epithelial ovarian cancer (EOC). However, in EOC, chemotherapy failure is mainly caused by platinum resistance. In this present study, we aimed to identify novel biomarkers for predicting platinum chemosensitivity. Fresh specimens of 16 serous high-grade ovarian cancer (HGSC) cases were collected during cytoreductive surgery. Isobaric tags were used to identify differentially expressed proteins in platinum-resistant samples (n = 8) and platinum-sensitive samples (n = 8). Compared to platinum-sensitive samples, 741 significantly differentially expressed proteins were detected, of which 325 were upregulated and 416 were downregulated. To validate the isobaric tags for relative and absolute quantification (iTRAQ) method, western blotting was performed on two upregulated proteins, angiomotin-like protein 1 (AMOTL1) and Lumican. The results showed that platinum-resistant tumor samples expressed significantly higher levels of AMOTL1 and Lumican than platinum-sensitive tumor samples. Altogether, we identified candidate proteins related to platinum resistance in ovarian cancer. Both AMOTL1 and Lumican seem to be promising biomarkers that could distinguish between platinum-resistant and platinum-sensitive EOC.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136368236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cervical cancer (CC) is a leading cause of cancer-related deaths in women. During tumor development, transcriptional factors regulate the transcription of proto-oncogenes and tumor suppressor genes. We examined the possibility of using transcription factors as prognostic biomarkers for patients with cervical cancer. Single-cell RNA-sequencing data were downloaded from the Gene Expression Omnibus database to identify specific activated transcription factors in different types of cells from CC. Publicly available bulk RNA-sequencing and clinical data of CC were obtained to identify associated prognostic transcription factors using survival analysis and the random survival forest methods. Accuracy and effectiveness of the established transcription factor-related predictive random survival forest model were verified using training and test datasets. We identified specific activated transcription factors in tissue cells of cervical cancer. A 3-transcription factors (PBX4 (PBX Homeobox 4), EBF2 (EBF Transcription Factor 2) and ZNF696 (Zinc Finger Protein 696)) prognostic signature for patients with cervical cancer was constructed showing good survival prediction. Gene function enrichment analysis indicated a correlation between the prognostic characteristics and different signaling pathways associated with cancer. Using the random survival forest model based on the 3-transcription factor signature, patients with cervical cancer were stratified into low- and high-risk groups with significant variations in overall survival (p < 0.001). The area under the curve of the time-dependent receiver operator characteristic revealed a strong predictive accuracy for training and test datasets of the corresponding signature. CC has cellular heterogeneity of transcriptional activation. Our analyses provide a novel transcription factor-associated prognostic model for CC. These transcription factors could be used as effective prognostic biomarkers and potential therapeutic targets for patients with cervical cancer.
{"title":"Development of a novel transcription factor signature for accurate cervical cancer prognosis","authors":"","doi":"10.22514/ejgo.2023.079","DOIUrl":"https://doi.org/10.22514/ejgo.2023.079","url":null,"abstract":"Cervical cancer (CC) is a leading cause of cancer-related deaths in women. During tumor development, transcriptional factors regulate the transcription of proto-oncogenes and tumor suppressor genes. We examined the possibility of using transcription factors as prognostic biomarkers for patients with cervical cancer. Single-cell RNA-sequencing data were downloaded from the Gene Expression Omnibus database to identify specific activated transcription factors in different types of cells from CC. Publicly available bulk RNA-sequencing and clinical data of CC were obtained to identify associated prognostic transcription factors using survival analysis and the random survival forest methods. Accuracy and effectiveness of the established transcription factor-related predictive random survival forest model were verified using training and test datasets. We identified specific activated transcription factors in tissue cells of cervical cancer. A 3-transcription factors (PBX4 (PBX Homeobox 4), EBF2 (EBF Transcription Factor 2) and ZNF696 (Zinc Finger Protein 696)) prognostic signature for patients with cervical cancer was constructed showing good survival prediction. Gene function enrichment analysis indicated a correlation between the prognostic characteristics and different signaling pathways associated with cancer. Using the random survival forest model based on the 3-transcription factor signature, patients with cervical cancer were stratified into low- and high-risk groups with significant variations in overall survival (p < 0.001). The area under the curve of the time-dependent receiver operator characteristic revealed a strong predictive accuracy for training and test datasets of the corresponding signature. CC has cellular heterogeneity of transcriptional activation. Our analyses provide a novel transcription factor-associated prognostic model for CC. These transcription factors could be used as effective prognostic biomarkers and potential therapeutic targets for patients with cervical cancer.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136368238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Endometrial carcinoma (EC) is an epithelial malignant tumor that occurs in the endometrium. It is of great significance to explore new targets for improving the prognosis of endometrial cancer. Chikusetsusaponin Iva (CHI) is a plant compound extracted from Panacis japonica which has multiple biological activities, including anti-inflammation and anti-tumor effects. However, its possible effects on EC are unclear. Herein, we found that CHI inhibited EC cell proliferation and cell cycle, confirmed by colony formation and flow cytometry (FCM) assays. The results further confirmed that CHI stimulated the apoptosis of EC cells. Furthermore, we noticed that CHI treatment induced reactive oxygen species (ROS) in EC cells. In addition, it could suppress the Microtubule-Associated Protein Kinase (MAPK) pathway in EC cells, thereby affecting cell proliferation and apoptosis. Therefore, CHI could serve as a potential drug for EC treatment.
子宫内膜癌(EC)是发生在子宫内膜的上皮性恶性肿瘤。探索改善子宫内膜癌预后的新靶点具有重要意义。Chikusetsusaponin Iva (CHI)是从日本人参中提取的一种具有抗炎、抗肿瘤等多种生物活性的植物化合物。然而，它对EC的可能影响尚不清楚。在此，我们发现CHI抑制EC细胞的增殖和细胞周期，通过集落形成和流式细胞术(FCM)实验证实了这一点。结果进一步证实了CHI刺激EC细胞凋亡。此外，我们注意到CHI处理诱导EC细胞的活性氧(ROS)。此外，它可以抑制EC细胞的微管相关蛋白激酶(microtubuleassociated Protein Kinase, MAPK)通路，从而影响细胞的增殖和凋亡。因此，CHI可作为治疗EC的潜在药物。
{"title":"Chikusetsusaponin Iva induces apoptosis and inhibits proliferation in endometrial cancer via promoting reactive oxygen species (ROS) production","authors":"","doi":"10.22514/ejgo.2023.068","DOIUrl":"https://doi.org/10.22514/ejgo.2023.068","url":null,"abstract":"Endometrial carcinoma (EC) is an epithelial malignant tumor that occurs in the endometrium. It is of great significance to explore new targets for improving the prognosis of endometrial cancer. Chikusetsusaponin Iva (CHI) is a plant compound extracted from Panacis japonica which has multiple biological activities, including anti-inflammation and anti-tumor effects. However, its possible effects on EC are unclear. Herein, we found that CHI inhibited EC cell proliferation and cell cycle, confirmed by colony formation and flow cytometry (FCM) assays. The results further confirmed that CHI stimulated the apoptosis of EC cells. Furthermore, we noticed that CHI treatment induced reactive oxygen species (ROS) in EC cells. In addition, it could suppress the Microtubule-Associated Protein Kinase (MAPK) pathway in EC cells, thereby affecting cell proliferation and apoptosis. Therefore, CHI could serve as a potential drug for EC treatment.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136115070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Platinum based combined chemotherapy have been proved to be the most effective drugs for the ovarian cancer treatment, but it is difficult to treat cisplatin resistant ovarian cancer. Carbobenzoxy-L-leucy-L-Leucyl-L-Leucinal (MG132) is a reversible tripeptide aldehyde proteasome inhibitor, the purpose of this study was to observe the effect of MG132 on cisplatin resistant ovarian cancer SKOV3 cell and OVCAR-3 cell the expression of autophagy and apoptosis related factors. The cells were divided into four groups: control, MG132, cisplatin, MG132 and cisplatin combination groups. Cell growth was detected by cell counting kit-8 (CCK-8) assay. The apoptotic rates of cells and the cell cycle were detected by a flow cytometer (FCM). The Beclin1, Light chain 3 (LC3) and Caspase3 was detected by western blotting and reverse transcription-polymerase chain reaction (RT-PCR). Detection of apoptotic bodies by 4,6-Diamidino-2-phenylindole dihydrochloride (DAPI) staining. CCK-8 assay demonstrated that cell survival rate in the combination groups was lower than monotherapy group. FCM showed that apoptotic rates in the combination groups was higher than monotherapy group (p < 0.05). Western blotting and RT-PCR detected that Beclin1, LC3 and Caspase3 in the combination group were higher than monotherapy group (p < 0.05). DAPI staining showed the production of apoptotic bodies in the combination group and MG132 group. In conclusion, MG132 can inhibit the growth of cisplatin resistant ovarian cancer SKOV3 and OVCAR-3 cells, its inhibitory effect is related to apoptosis and autophagy, and it is expected to be a synergistic antitumor effect with cisplatin.
{"title":"The role of proteasome inhibitor MG132 in cisplatin resistant ovarian cancer","authors":"","doi":"10.22514/ejgo.2023.055","DOIUrl":"https://doi.org/10.22514/ejgo.2023.055","url":null,"abstract":"Platinum based combined chemotherapy have been proved to be the most effective drugs for the ovarian cancer treatment, but it is difficult to treat cisplatin resistant ovarian cancer. Carbobenzoxy-L-leucy-L-Leucyl-L-Leucinal (MG132) is a reversible tripeptide aldehyde proteasome inhibitor, the purpose of this study was to observe the effect of MG132 on cisplatin resistant ovarian cancer SKOV3 cell and OVCAR-3 cell the expression of autophagy and apoptosis related factors. The cells were divided into four groups: control, MG132, cisplatin, MG132 and cisplatin combination groups. Cell growth was detected by cell counting kit-8 (CCK-8) assay. The apoptotic rates of cells and the cell cycle were detected by a flow cytometer (FCM). The Beclin1, Light chain 3 (LC3) and Caspase3 was detected by western blotting and reverse transcription-polymerase chain reaction (RT-PCR). Detection of apoptotic bodies by 4,6-Diamidino-2-phenylindole dihydrochloride (DAPI) staining. CCK-8 assay demonstrated that cell survival rate in the combination groups was lower than monotherapy group. FCM showed that apoptotic rates in the combination groups was higher than monotherapy group (p < 0.05). Western blotting and RT-PCR detected that Beclin1, LC3 and Caspase3 in the combination group were higher than monotherapy group (p < 0.05). DAPI staining showed the production of apoptotic bodies in the combination group and MG132 group. In conclusion, MG132 can inhibit the growth of cisplatin resistant ovarian cancer SKOV3 and OVCAR-3 cells, its inhibitory effect is related to apoptosis and autophagy, and it is expected to be a synergistic antitumor effect with cisplatin.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136115078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Endometrial carcinoma is a common malignancy among peri-menopausal and menopausal females, even among some women of reproductive age. The treatment approach to endometrial cancer is a platinum-based regimen combined with paclitaxel, which may be unsatisfactory. A copper-mediated binding of lipoylated constituents of tricarboxylic acid cycle has been found recently, which brings about lethal protein stress and cell death, a phenomenon termed cuproptosis. As an innovative method of cell death, cuproptosis could be designed for cancer treatment and many aspects remain unaddressed. In our study, clinical, genomic, and mutational profiles of uterine corpus endometrial carcinoma (UCEC) patients were obtained from The Cancer Genome Atlas and cuproptosis-related genes and long non-coding RNAs (lncRNAs) were acquired thereafter. Co-expression and Cox regression analyses led to the development of a prognostic signature. Patients were separated into two groups (high- and low-risk groups) and survival analysis, risk score calculation, multivariate Cox analysis, and subgroup validation were implemented to determine the utility of the signature. Differentially expressed genes (DEGs) between the two groups were subjected to Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses. Immune-related functional analysis and tumor mutation burden (TMB) analysis were performed. Three independent high-risk cuproptosis-related lncRNAs were finally confirmed and incorporated into the prognostic model, including BX322234.1, LINC01545 and LINC01224. Areas under the curve for 1-, 3- and 5-year survival were 0.717, 0.688 and 0.714, respectively. The risk model served as an independent factor to predict prognosis. Patients with high-risk and low TMB tended to have poor prognoses. Enrichment analysis demonstrated that DEGs were mostly associated with immune responses. In conclusion, the three high-risk cuproptosis-related lncRNAs could predict the prognosis of UCEC patients with higher power, where patients with high-risk and low TMB are prone to have the worst prognosis, which broadens the pattern of clinical treatment and applications.
{"title":"Identification of a 3-cuproptosis-associated-lncRNA-signature that predicts the prognosis of endometrial cancer patients","authors":"","doi":"10.22514/ejgo.2023.073","DOIUrl":"https://doi.org/10.22514/ejgo.2023.073","url":null,"abstract":"Endometrial carcinoma is a common malignancy among peri-menopausal and menopausal females, even among some women of reproductive age. The treatment approach to endometrial cancer is a platinum-based regimen combined with paclitaxel, which may be unsatisfactory. A copper-mediated binding of lipoylated constituents of tricarboxylic acid cycle has been found recently, which brings about lethal protein stress and cell death, a phenomenon termed cuproptosis. As an innovative method of cell death, cuproptosis could be designed for cancer treatment and many aspects remain unaddressed. In our study, clinical, genomic, and mutational profiles of uterine corpus endometrial carcinoma (UCEC) patients were obtained from The Cancer Genome Atlas and cuproptosis-related genes and long non-coding RNAs (lncRNAs) were acquired thereafter. Co-expression and Cox regression analyses led to the development of a prognostic signature. Patients were separated into two groups (high- and low-risk groups) and survival analysis, risk score calculation, multivariate Cox analysis, and subgroup validation were implemented to determine the utility of the signature. Differentially expressed genes (DEGs) between the two groups were subjected to Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses. Immune-related functional analysis and tumor mutation burden (TMB) analysis were performed. Three independent high-risk cuproptosis-related lncRNAs were finally confirmed and incorporated into the prognostic model, including BX322234.1, LINC01545 and LINC01224. Areas under the curve for 1-, 3- and 5-year survival were 0.717, 0.688 and 0.714, respectively. The risk model served as an independent factor to predict prognosis. Patients with high-risk and low TMB tended to have poor prognoses. Enrichment analysis demonstrated that DEGs were mostly associated with immune responses. In conclusion, the three high-risk cuproptosis-related lncRNAs could predict the prognosis of UCEC patients with higher power, where patients with high-risk and low TMB are prone to have the worst prognosis, which broadens the pattern of clinical treatment and applications.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136260089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The immunotherapy of endometrial cancer (EC) has gradually attracted attention and metabolic reprogramming is associate with tumor immune infiltration. Our goal was to use proteome analysis to examine the role of immune-related metabolic genes (IRMGs) in EC. Data-independent acquisition mass spectrometry (DIA-MS) was performed on 20 EC patients, consisting of 10 high-grade and 10 low-grade cancer tissues. IRMGs were screened using Spearman correlation, and an immune-related metabolic prognosis signature (IRMPS) was constructed based on the Cancer Genome Atlas-Uterine Corpus Endometrioid Carcinoma (TCGA-UCEC) cohort using the least absolute shrinkage and selection operator (LASSO) regression analysis. We also investigated differences between different risk groups in terms of prognostic value, clinical potency, immune characteristics and therapy response. In total, 285 differentially expressed genes (DEGs) were acquired via DIA-MS. Subsequently, metabolic-DEGs and immune-DEGs were analyzed by Spearman correlation to identify 41 IRMGs. Finally, seven IRMGs, including NADH dehydrogenase (ubiquinone) 1 alpha subcomplex subunit 2 (NDUFA2), AMPK-alpha2 (PRKAA2), syntaxin binding protein 1 (STXBP1), NADH dehydrogenase (ubiquinone) 1 beta subcomplex subunit 9 (NDUFB9), ribosomal protein S27-like (RPS27L), lysolecithin acyltransferase 2 (LPCAT2) and uridine monophosphate synthetase (UMPS) were identified to establish a prognosis signature. The risk score was determined as an independent prognostic indicator, and patients in the IRMPS-high group was strong linked with adverse prognosis for EC. Additionally, IRMPS was closely related with tumor immune infiltration. Notably, the IRMPS-low group had better immune checkpoint inhibitors (ICI) treatment response and more sensitive to chemotherapy drugs. In conclusion, IRMPS can serve as a precise prognostic tool to guide the personalized treatment of EC patients.
{"title":"Identification of an immune-related metabolic gene signature to predict possible prognosis in endometrial cancer and reveals immune landscape feature","authors":"","doi":"10.22514/ejgo.2023.072","DOIUrl":"https://doi.org/10.22514/ejgo.2023.072","url":null,"abstract":"The immunotherapy of endometrial cancer (EC) has gradually attracted attention and metabolic reprogramming is associate with tumor immune infiltration. Our goal was to use proteome analysis to examine the role of immune-related metabolic genes (IRMGs) in EC. Data-independent acquisition mass spectrometry (DIA-MS) was performed on 20 EC patients, consisting of 10 high-grade and 10 low-grade cancer tissues. IRMGs were screened using Spearman correlation, and an immune-related metabolic prognosis signature (IRMPS) was constructed based on the Cancer Genome Atlas-Uterine Corpus Endometrioid Carcinoma (TCGA-UCEC) cohort using the least absolute shrinkage and selection operator (LASSO) regression analysis. We also investigated differences between different risk groups in terms of prognostic value, clinical potency, immune characteristics and therapy response. In total, 285 differentially expressed genes (DEGs) were acquired via DIA-MS. Subsequently, metabolic-DEGs and immune-DEGs were analyzed by Spearman correlation to identify 41 IRMGs. Finally, seven IRMGs, including NADH dehydrogenase (ubiquinone) 1 alpha subcomplex subunit 2 (NDUFA2), AMPK-alpha2 (PRKAA2), syntaxin binding protein 1 (STXBP1), NADH dehydrogenase (ubiquinone) 1 beta subcomplex subunit 9 (NDUFB9), ribosomal protein S27-like (RPS27L), lysolecithin acyltransferase 2 (LPCAT2) and uridine monophosphate synthetase (UMPS) were identified to establish a prognosis signature. The risk score was determined as an independent prognostic indicator, and patients in the IRMPS-high group was strong linked with adverse prognosis for EC. Additionally, IRMPS was closely related with tumor immune infiltration. Notably, the IRMPS-low group had better immune checkpoint inhibitors (ICI) treatment response and more sensitive to chemotherapy drugs. In conclusion, IRMPS can serve as a precise prognostic tool to guide the personalized treatment of EC patients.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135495188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The diagnostic performances of colposcopy and Loop Electrosurgical Excision Proce-dure (LEEP) results in gynecology and gynecological oncology surgical services were evaluated. Their differences regarding biopsy numbers were investigated. The other objective was to examine factors associated with recurrence and residual lesions after LEEP. This study included the cytology results of 1217 women undergone colposcopy at our hospital colposcopy unit between 2012 and 2017. The colposcopicsensitivity, specificity, positive predictive value and negative predictive value were calculated based on LEEP results. The qualitative data were compared by employing Chi-square and Fisher’s exact tests. χ2 predicted the relation between age and number of involved margins with recurrent disease. Moreover, it predicted the link between age, cytology and number of relevant margins with residual disease. There was no significant difference regarding the diagnostic performance of two groups when LEEP was determined as the gold standard against colposcopy. The diagnostic accuracy rate was 1.83 times higher when more than 2 biopsies were taken compared to 2 or fewer. A significant increase was observed in the residual rate among women having pre-LEEP high-risk human papillomavirus (HR-HPV) positive tests compared to those with HR-HPV negative tests (48.0% vs. 15.4%, p = 0.04). Women with ≥ High grade squamous intraepithelial lesion (HSIL)-positive margins in the first conization exhibited higher residual rates compared to those with High grade squamous intraepithelial lesion (LSIL)-positive margins (50.7% vs. 9.5%, p < 0.001). Patients ofpositive surgical margins, residual lesions and cervical intraepithelial neoplasia (CIN) with HPV 16 had higher probability of persistent HPV infection after conization. There was no significant difference pertaining to the diagnostic performance of two groups. HPV 16+ and the positive surgical margin were the predictive of recurrence.
评价阴道镜和环形电切术(LEEP)结果在妇科和妇科肿瘤外科服务中的诊断性能。研究了他们在活检次数方面的差异。另一个目的是检查与LEEP后复发和残留病变相关的因素。本研究纳入2012 - 2017年在我院阴道镜科室行阴道镜检查的1217例女性的细胞学结果。根据LEEP结果计算阴道镜敏感性、特异性、阳性预测值和阴性预测值。采用卡方检验和Fisher精确检验对定性资料进行比较。χ2预测年龄、受累切缘数与复发的关系。此外，它预测了年龄、细胞学和与残留疾病相关的边缘数量之间的联系。当LEEP被确定为对阴道镜检查的金标准时，两组的诊断性能无显著差异。2例以上活检的诊断准确率是2例以下活检的1.83倍。leep前高危人乳头瘤病毒(HR-HPV)检测阳性的妇女的残留率显著高于HR-HPV阴性的妇女(48.0%对15.4%，p = 0.04)。与高级别鳞状上皮内病变(LSIL)边缘阳性的女性相比，第一次穿刺时具有≥高级别鳞状上皮内病变(HSIL)阳性边缘的女性表现出更高的残留率(50.7% vs 9.5%， p <0.001)。手术切缘阳性、残留病变和宫颈上皮内瘤变(CIN)合并HPV 16的患者在锥形化后持续感染HPV的可能性更高。两组在诊断表现上无显著差异。HPV 16+和手术切缘阳性是复发的预测因素。
{"title":"Evaluation of colposcopy and LEEP results performed in gynecology and gynecological oncology surgery services","authors":"","doi":"10.22514/ejgo.2023.071","DOIUrl":"https://doi.org/10.22514/ejgo.2023.071","url":null,"abstract":"The diagnostic performances of colposcopy and Loop Electrosurgical Excision Proce-dure (LEEP) results in gynecology and gynecological oncology surgical services were evaluated. Their differences regarding biopsy numbers were investigated. The other objective was to examine factors associated with recurrence and residual lesions after LEEP. This study included the cytology results of 1217 women undergone colposcopy at our hospital colposcopy unit between 2012 and 2017. The colposcopicsensitivity, specificity, positive predictive value and negative predictive value were calculated based on LEEP results. The qualitative data were compared by employing Chi-square and Fisher’s exact tests. χ2 predicted the relation between age and number of involved margins with recurrent disease. Moreover, it predicted the link between age, cytology and number of relevant margins with residual disease. There was no significant difference regarding the diagnostic performance of two groups when LEEP was determined as the gold standard against colposcopy. The diagnostic accuracy rate was 1.83 times higher when more than 2 biopsies were taken compared to 2 or fewer. A significant increase was observed in the residual rate among women having pre-LEEP high-risk human papillomavirus (HR-HPV) positive tests compared to those with HR-HPV negative tests (48.0% vs. 15.4%, p = 0.04). Women with ≥ High grade squamous intraepithelial lesion (HSIL)-positive margins in the first conization exhibited higher residual rates compared to those with High grade squamous intraepithelial lesion (LSIL)-positive margins (50.7% vs. 9.5%, p < 0.001). Patients ofpositive surgical margins, residual lesions and cervical intraepithelial neoplasia (CIN) with HPV 16 had higher probability of persistent HPV infection after conization. There was no significant difference pertaining to the diagnostic performance of two groups. HPV 16+ and the positive surgical margin were the predictive of recurrence.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135495190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The aim of this study was to assess the elapsed time for symptomatic women with endometrial carcinoma to achieve diagnosis and treatment and its impact on staging and survival. A cohort study was carried out with 430 women divided into in two groups: “Type I” (n = 289, endometrioid carcinoma grade 1 or 2); “Type II” (n = 141, nonendometrioid, endometrioid carcinoma grade 3, or carcinosarcoma). Clinical information, diagnostic methods, histology, staging, and time elapsed between symptoms-diagnosis-treatment were considered. Descriptive, survival, and regression analyses were performed. The symptom-to-diagnosis interval was 284 and 249 days in Types I and II (p = 0.014), with only 30% getting a diagnosis within 90 days. The diagnosis-to-treatment interval was shorter for Type II (100 vs. 123 days for Type I; p = 0.001). Only 12.5% of Type I and 22.7% of Type II started treatment within 60 days after diagnosis. There was no association between symptom-to-diagnosis interval and staging (p = 0.377). The symptom-to-treatment interval did not change the overall survival for Type I and had a paradoxical effect for Type II, with greater overall survival associated with a longer elapsed time (p = 0.003). Symptomatic Brazilian women with endometrial carcinomas showed very long wait times for diagnosis and treatment, and less than 23% started treatment within the regulatory period of 60 days. This critical situation does not exhibit any clear effect on cancer staging or overall survival, possibly counterbalanced by the faster care of patients with a poor prognosis, such as those with Type II endometrial carcinomas.
{"title":"Symptomatic women experience long waits for endometrial cancer diagnosis and treatment in Brazil","authors":"","doi":"10.22514/ejgo.2023.063","DOIUrl":"https://doi.org/10.22514/ejgo.2023.063","url":null,"abstract":"The aim of this study was to assess the elapsed time for symptomatic women with endometrial carcinoma to achieve diagnosis and treatment and its impact on staging and survival. A cohort study was carried out with 430 women divided into in two groups: “Type I” (n = 289, endometrioid carcinoma grade 1 or 2); “Type II” (n = 141, nonendometrioid, endometrioid carcinoma grade 3, or carcinosarcoma). Clinical information, diagnostic methods, histology, staging, and time elapsed between symptoms-diagnosis-treatment were considered. Descriptive, survival, and regression analyses were performed. The symptom-to-diagnosis interval was 284 and 249 days in Types I and II (p = 0.014), with only 30% getting a diagnosis within 90 days. The diagnosis-to-treatment interval was shorter for Type II (100 vs. 123 days for Type I; p = 0.001). Only 12.5% of Type I and 22.7% of Type II started treatment within 60 days after diagnosis. There was no association between symptom-to-diagnosis interval and staging (p = 0.377). The symptom-to-treatment interval did not change the overall survival for Type I and had a paradoxical effect for Type II, with greater overall survival associated with a longer elapsed time (p = 0.003). Symptomatic Brazilian women with endometrial carcinomas showed very long wait times for diagnosis and treatment, and less than 23% started treatment within the regulatory period of 60 days. This critical situation does not exhibit any clear effect on cancer staging or overall survival, possibly counterbalanced by the faster care of patients with a poor prognosis, such as those with Type II endometrial carcinomas.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136115277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cervical cancer is the second most common malignant tumor in women. This study aimed to investigate the intake and effect of nab-paclitaxel in chemotherapy for patients with advanced cervical cancer, to collect more evidence for clinical medication. A total of 96 patients with advanced cervical cancer who received chemotherapy treatment in Wuhan Third Hospital from July 2021 to July 2022 were randomly divided into observation group (treated with nab-paclitaxel + cisplatin) and control group (treated with paclitaxel + cisplatin) by envelope method. The short-term efficacy, tumor markers, immune function indicators, adverse reactions and quality of life of both groups were observed and compared with each other. After treatment, serum tumor markers were notably decreased, while cluster of differentiation 4 (CD4)+ and CD4+/cluster of differentiation 8 (CD8)+ were clearly increased in both groups. The observation group showed the improvement effect of each index in a statistically significant manner (p < 0.05) than the control group. The effective disease control rate of observation group was higher than that of the control group while the incidence of treatment-related adverse reactions in the observation group was higher than that of the control group. The observation group indicated improved effective rate of Karnofsky Performance Scale (KPS) than the control group (p < 0.05). In conclusion, nab-paclitaxel has significant advantages in chemotherapy for patients suffering from advanced cervical cancer, which can strengthen immune function, improve the effectiveness of disease control, and promote the improvement of functional status.
{"title":"Study on the intake and efficacy of nab-paclitaxel in patients with advanced cervical cancer","authors":"","doi":"10.22514/ejgo.2023.061","DOIUrl":"https://doi.org/10.22514/ejgo.2023.061","url":null,"abstract":"Cervical cancer is the second most common malignant tumor in women. This study aimed to investigate the intake and effect of nab-paclitaxel in chemotherapy for patients with advanced cervical cancer, to collect more evidence for clinical medication. A total of 96 patients with advanced cervical cancer who received chemotherapy treatment in Wuhan Third Hospital from July 2021 to July 2022 were randomly divided into observation group (treated with nab-paclitaxel + cisplatin) and control group (treated with paclitaxel + cisplatin) by envelope method. The short-term efficacy, tumor markers, immune function indicators, adverse reactions and quality of life of both groups were observed and compared with each other. After treatment, serum tumor markers were notably decreased, while cluster of differentiation 4 (CD4)+ and CD4+/cluster of differentiation 8 (CD8)+ were clearly increased in both groups. The observation group showed the improvement effect of each index in a statistically significant manner (p < 0.05) than the control group. The effective disease control rate of observation group was higher than that of the control group while the incidence of treatment-related adverse reactions in the observation group was higher than that of the control group. The observation group indicated improved effective rate of Karnofsky Performance Scale (KPS) than the control group (p < 0.05). In conclusion, nab-paclitaxel has significant advantages in chemotherapy for patients suffering from advanced cervical cancer, which can strengthen immune function, improve the effectiveness of disease control, and promote the improvement of functional status.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136115280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：